BD has expanded a Class I Alaris recall to cover 15 additional pump infusion sets, the company said Friday. The Food and Drug Administration posted the company's notice on Monday. The company added ...
The U.S. FDA said that BD (NYSE:BDX) has expanded its Class I voluntary recall to inform customers about the worst-case performance of the BD Alaris Pump Module model 8100 when used with certain ...
The BD Alaris infusion sets from Becton Dickinson promise something nurses and patients crave on long shifts: fewer line problems, smoother drug delivery, and small touches that make tubing feel a bit ...
FRANKLIN LAKES, N.J., July 18, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. A voluntary safety recall of widely used Alaris infusion ...
Since the start of 2020, BD’s Alaris infusion pumps have been the subject of more than half-a-dozen Class I hardware and software recalls, a handful of cybersecurity warnings and a years-long ...
A new group of recalls for a repair piece installed in some of BD’s Alaris infusion pumps joins more than a dozen others on the long list of serious recalls involving the device in the last decade.
Becton, Dickinson and Company’s BDX, or popularly known as BD, initiated the recall of its infusion pumps last month after customer reports indicated software issues, potentially leading to inaccurate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results